During the last 100 years, medical practitioners and women alike are used to talking about bio-identical hormone replacement therapy in menopause medicine. But there is a problem with this terminology. In reality, you can't replace your hormones. In menopause medicine, we have all been accustomed to talking about bio-identical hormone replacement therapy or BHRT. Truth be told, hormones aren't really bio-identical, and they cannot be replaced.
More than two million women in the U.S. use customized hormones for menopause symptoms.
The primary objective of the study shall be to examine clinical outcomes and quality of life indicators of patients receiving BHT at 10 to 12 primary care provider's practices.
Ultimately, the findings of the study would be the basis in identifying the most effective dosage and pattern of BHT administration.
This study, whose participants are women between the ages of 35 and 60 who are current users of compounded bioidentical hormone therapy (BHT), is an observational one. Quality of life, symptom relief and impact of BHT on physical health like breast, endometrial and cardiovascular measures are among the variables that shall be examined in this research.
Results will be used to design a prospective, randomized clinical trial with the goal of standardizing BHT dosing and administration patterns.
Among the chief goals of the study are: (1) to evaluate the quality of life indicators of the patients who are currently receiving bio-identical hormone replacement therapy at 10 to 12 practices of primary care providers (2) to check the effectiveness, safety and overall quality of life of subjects who are using 1 among 3 dosing patterns (3) to monitor the women's lab results (4) to track the adverse effects experienced by the respondents in relation to BHT and (5) to assess the compounding pharmacies' compliance to the standards.
This article was added on Thursday 15 October, 2009.
